Advertisement

Topics

Trod Medical Receives a New Patent Allowance for Prostate Focal Therapy Encage™ Device

04:00 EDT 1 Aug 2016 | b3C NEWSWIRE

TROD medical logo

Leuven, Belgium, August 1, 2016 / B3C newswire / -- Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled “Method to remove a tumor using a percutaneous surgical instrument”.

The patent covers a surgical technique used with Trod Medical’s Encage™ radio frequency ablation device, including the technique of enlarging the margin of the tissue destruction area, particularly important in Prostate Focal Therapy.

“This new patent adds an additional layer of protection, even beyond the other families of patents we have from Encage’s original design and guiding systems”, said Andre Faure, CEO of Trod Medical. He continued, “This, combined with Encage’s superior clinical outcomes, will put Trod in a dominant position in this very significant and growing market”.

TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.


About TROD Medical NV
TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.

Trod Medical’s proprietary product, Encage, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

TROD Medical is a private venture-backed company with headquarters in Leuven (Belgium) and facilities in the Tampa Bay area (USA), and Paris (France).


Contacts

TROD Medical
Andre Faure, CEO
andre.faure@trodmedical.com

Instinctif Partners
Daniel Gooch/Dr Christelle Kerouedan
+44 (0)20 7457 2020
trod@instinctif.com

Original Article: Trod Medical Receives a New Patent Allowance for Prostate Focal Therapy Encage™ Device

NEXT ARTICLE

More From BioPortfolio on "Trod Medical Receives a New Patent Allowance for Prostate Focal Therapy Encage™ Device"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...